Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (PSTV) announced plans to present data from ongoing clinical trials involving its investigational targeted radiotherapeutic, rhenium-186 obisbemeda, at the Society for Neuro-Oncology's 27th Annual Meeting between November 16-20, 2022. Data on recurrent glioblastoma and leptomeningeal metastases will be shared through oral presentations, with further insights into pediatric brain cancer planned for a poster session. Notable presentations will occur on November 19, including initial clinical experiences from the ReSPECT trials, which aim to provide innovative treatments for difficult-to-treat cancers.
Plus Therapeutics (PSTV) announced that the WHO has assigned the non-proprietary name Rhenium (186Re) obisbemeda to its lead investigational targeted radiotherapeutic, formerly known as 186RNL. This milestone aligns with the company's plans to advance towards mid- and late-stage clinical development, including a Phase 2 trial for recurrent glioblastoma by the end of 2022. The company focuses on innovative treatments for cancer, utilizing advanced liposomal encapsulation technology.
Plus Therapeutics, Inc. (PSTV) announced a $17.6 million grant from CPRIT to support the development of 186RNL for leptomeningeal metastases. The company completed cGMP manufacturing for this investigational drug and plans to initiate the ReSPECT-GBM Phase 2 trial for recurrent glioblastoma in Q4 2022. Financially, PSTV reported a net loss of $5.2 million for Q3 2022, with cash reserves of $20.3 million. The company believes its funding is sufficient to support operations through 2025, highlighting significant progress in clinical trials and funding commitments.
Plus Therapeutics (PSTV) recently presented findings from its ReSPECT-LM and ReSPECT-GBM Phase 1 clinical trials at the 35th Annual Congress of the European Association of Nuclear Medicine. Both trials evaluated the investigational drug Rhenium-186 NanoLiposome (186RNL) for treating leptomeningeal metastases and recurrent glioblastoma. Results indicated that treatment was well tolerated, with no dose-limiting toxicities and significant decreases in spinal fluid tumor cell counts (46%-92%). A $17.6 million grant from CPRIT supports ongoing trials, with further data expected by year-end.
Plus Therapeutics, a clinical-stage pharmaceutical company, announced that CEO Marc Hedrick will present at the ThinkEquity Conference on October 26, 2022, at 3:00 p.m. ET in New York City. The company is focused on developing innovative radiotherapeutics for rare cancers. Investors can arrange meetings with management during the conference. An archived presentation will be available on their website for 90 days post-event. Plus Therapeutics emphasizes its nanotechnology platform and liposomal encapsulation technology aimed at improving drug delivery for cancer treatment.
Plus Therapeutics, Inc. (PSTV) will report its third quarter 2022 financial results on October 20, 2022, after market close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide corporate updates. The live webcast can be accessed through their investor relations page. The company focuses on developing innovative radiotherapeutics for challenging cancers and utilizes a proprietary nanotechnology platform for drug delivery.
Plus Therapeutics (PSTV) announced that Dr. Andrew Brenner will host a live webinar on October 9, 2022, focusing on a new targeted radiation therapy for leptomeningeal metastases related to breast and lung cancers. This session is part of the Musella Foundation Webinar Series. Leptomeningeal metastases pose significant treatment challenges, and the webinar aims to educate patients about potential therapies. Plus Therapeutics is a clinical-stage pharmaceutical company developing innovative treatments for cancer, leveraging advanced delivery technologies.
Plus Therapeutics (PSTV) announced that its data on Leptomeningeal metastases has been recognized as a “Top Rated Oral Presentation” by EANM. The company will present findings from ongoing clinical trials on its investigational drug, Rhenium-186 NanoLiposome (186RNL), for treating recurrent glioblastoma and leptomeningeal metastases at the 35th Annual Congress of EANM in Barcelona from October 15-19, 2022. The presentations will detail safety and feasibility trials for 186RNL, highlighting its potential in challenging cancer treatments.
Plus Therapeutics (PSTV) has secured a $17.6 million grant from CPRIT to fund the development of its lead investigational treatment, Rhenium-186 NanoLiposome, for leptomeningeal metastases. This funding, expected to be received by October 31, 2022, allows for $3.7 million in Year 1, $6.7 million in Year 2, and $7.2 million in Year 3, extending the company's cash runway through 2025. As of June 30, 2022, Plus Therapeutics reported $18.1 million in cash, bolstering its financial position for ongoing clinical trials and operational activities.
Plus Therapeutics announced Phase 1 results for 186RNL, showing significant safety and survival benefits in patients with recurrent glioblastoma. The trial, presented at ESMO 2022, demonstrated a median overall survival of 22.9 months for patients receiving over 100 Gray of radiation, compared to 5.6 months for lower doses. The company will advance to Phase 2, funded by the NIH, to explore expanded dosing and larger tumors. Observations include no dose-limiting toxicities and enhanced radiation delivery potential, marking a promising step towards treatment advancement.